Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin

Tai Jan Chiu, Shih Hung Yang, Sz Chi Chiu, Shun Wen Hsueh, Nai Jung Chiang, Chung Pin Li, Li Yuan Bai, Fu Ming Cheng, Shih Chang Chuang, Yan Shen Shan, De Chuan Chan, Li Tzong Chen, Chia Jui Yen, Cheng Ming Peng, Yung Yeh Su, Yen Yang Chen, Jen Shi Chen, Wen Chi Chou

研究成果: Article同行評審

摘要

Background: Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan. This study investigated the effect of conventional irinotecan treatment in mPDAC patients receiving nal-IRI+5-FU/LV by analyzing a population-based dataset. Methods: We reviewed 667 consecutive mPDAC patients treated with nal-IRI+5-FU/LV between August 2018 and November 2020 at Taiwanese medical centers. Eighty-six patients previously treated with conventional irinotecan were matched to 86 patients not treated with conventional irinotecan, following propensity matching for age, sex, performance status, metastatic organ site, pre-treatment carbohydrate antigen 19-9 level, lines of prior chemotherapy treatment, and time from first-line treatment to nal-IRI+5-FU/LV therapy. Results: The median overall survival and time-to-treatment failure were 4.8 and 2.6 vs 4.1 and 2.1 months, respectively, for patients who were and were not previously treated with conventional irinotecan. The tumor response and disease control rates were 5.8% and 32.6% vs 5.8% and 37.2%, respectively, for patients previously treated and not treated with conventional irinotecan. No significant differences were observed in survival times and tumor response rates between the two groups. Conclusions: Previous conventional irinotecan treatment does not compromise the efficacy of subsequent nal-IRI+5-FU/LV treatment in mPDAC patients.

原文English
頁(從 - 到)670-681
頁數12
期刊Journal of Hepato-Biliary-Pancreatic Sciences
29
發行號6
DOIs
出版狀態Published - 2022 6月

All Science Journal Classification (ASJC) codes

  • 手術
  • 肝病

指紋

深入研究「Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin」主題。共同形成了獨特的指紋。

引用此